There is an urgent need for strategies to combat dengue virus (DENV) infection; a major global threat. We reported that the cellular kinases AAK1 and GAK regulate intracellular trafficking of multiple viruses and that sunitinib and erlotinib, approved anticancer drugs with potent activity against these kinases, protect DENVinfected mice from mortality. Nevertheless, further characterization of the therapeutic potential and underlying mechanism of this approach is required prior to clinical evaluation. Here, we demonstrate that sunitinib/erlotinib combination achieves sustained suppression of systemic infection at approved dose in DENV-infected IFN-α/β and IFN-γ receptor-deficient mice. Nevertheless, treatment with these blood-brain barrier impermeable drugs delays, yet does not prevent, late-onset paralysis; a common manifestation in this immunodeficient mouse model but not in humans. Sunitinib and erlotinib treatment also demonstrates efficacy in human primary monocyte-derived dendritic cells. Additionally, DENV infection induces expression of AAK1 transcripts, but not GAK, via single-cell transcriptomics, and these kinases are important molecular targets underlying the anti-DENV effect of sunitinib and erlotinib. Lastly, sunitinib/erlotinib combination alters inflammatory cytokine responses in DENV-infected mice. These findings support feasibility of repurposing sunitinib/erlotinib combination as a host-targeted antiviral approach and contribute to understanding its mechanism of antiviral action.
Introduction
Dengue virus (DENV) is a global threat estimated to infect 390 million people annually (Bhatt et al., 2013) . The majority of individuals infected with any of the four DENV serotypes present with acute dengue fever. A fraction (∼5-20%) of dengue patients will progress to severe dengue manifested by bleeding, shock, organ failure, and death. The greatest risk factor for severe dengue is secondary infection with a heterologous DENV serotype causing antibody-dependent enhancement (ADE) (Katzelnick et al., 2017; Wang et al., 2017) . ADE has also been hindering the development of effective dengue vaccines, with recent data indicating increased dengue severity in vaccinated children (Halstead and Russell, 2016) . Moreover, there are currently no approved therapeutics for the treatment of dengue.
The current "one drug-one bug" antiviral approach is not easily scalable to address the unmet clinical need posed by emerging viruses and is often associated with emergence of drug resistance . Host-targeted antivirals have a potential for broadspectrum coverage and a higher barrier to resistance . The host-targeted approach is particularly attractive for the treatment of emerging viral infections lacking any treatment, given the opportunity to repurpose already approved, safe drugs that modulate specific host functions .
One cellular process that is usurped by multiple viruses is intracellular membrane traffic, which relies, in part, on the interactions between adaptor protein (AP) complexes and transmembrane cargo. The host cell kinases AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK) regulate clathrin-associated adaptor-cargo trafficking in the endocytic and secretory pathways (Ricotta et al., 2002; Umeda et al., 2000; Zhang et al., 2005) , in part by recruiting AP2 and AP1, respectively, to relevant membranes and enhancing their binding affinity for cargo (Ghosh and Kornfeld, 2003; Ricotta et al., 2002) . We and others have reported roles for APs in the lifecycles of multiple unrelated viruses (Bekerman et al., 2017; Bhattacharyya et al., 2011; Neveu et al., 2012 Neveu et al., , 2015 Ohno et al., 1997; Xiao et al., 2018) . Our work demonstrated that through AP1 and AP2 phosphorylation, AAK1 and GAK regulate early and late stages of the viral lifecycle, thereby representing "master regulators" of viral infection (Bekerman et al., 2017; Neveu et al., 2012 Neveu et al., , 2015 Xiao et al., 2018) . Moreover, we reported that sunitinib and erlotinib, approved anticancer drugs with potent binding to AAK1 and GAK (dissociation constant [KD] of 11 and 3.1 nM, respectively (Karaman et al., 2008) ), block entry and late stages in the lifecycle of the 4 DENV serotypes and multiple viruses in vitro (Bekerman et al., 2017; Kovackova et al., 2015; Neveu et al., 2012 Neveu et al., , 2015 Xiao et al., 2018) . Treatment with combinations of sunitinib and erlotinib revealed synergistic inhibition of DENV2 with a high genetic barrier to resistance (Bekerman et al., 2017) . In murine models of dengue and Ebola, 5-day treatment with the individual drugs provided partial or no protection, yet, consistent with our in vitro synergy results, sunitinib/erlotinib combinations significantly protected mice from morbidity and mortality (Bekerman et al., 2017) . Nevertheless, DENVinfected mice were monitored for 10-12 days only and relatively high drug doses were used. To support planned efforts to study the safety and efficacy of sunitinib/erlotinib combinations in dengue patients and potentially in Ebola patients in future outbreaks (ClinicalTrials.gov NCT02380625), it is therefore important to examine efficacy in preventing disease relapse, efficacy of lower dosing regimens, and antiviral effect in primary human cells. Moreover, whereas our mechanistic studies indicated that inhibition of intracellular viral trafficking mediates the anti-DENV effect of sunitinib and erlotinib, other mechanisms of antiviral action were incompletely characterized. Here, we integrate in vitro, ex vivo and in vivo data to address these gaps in knowledge and provide further evidence for the therapeutic potential of this repurposed approach and insight into its mechanism of action (MOA).
Materials and methods

Virus constructs
DENV2 (New Guinea C strain) Renilla reporter plasmid used for ex vivo assays was a gift from Pei-Yong Shi (Xie et al., 2013; Zou et al., 2011) . DENV 16681 plasmid (pD2IC-30P-NBX) used for transcriptomics was a gift from Claire Huang (CDC) (Huang et al., 2010) . Mouseadapted N124D/K128E DENV2 PL046 used for in vivo studies was a gift from Sujan Shresta (LIAI).
Cells
Huh7 (Apath LLC), BHK-21 (ATCC), and T-REx 293 (ThermoFisher) cells were grown in DMEM (Mediatech) supplemented with 10% FBS (Omega Scientific), nonessential amino acids, 1% L-glutamine, and 1% penicillin-streptomycin (ThermoFisher Scientific) (5% CO 2 , 37°C). C6/ 36 cells were grown in Leibovitz's L-15 media (CellGro) supplemented with 10% FBS and 1% HEPES (0% CO 2, 28°C). (Rodriguez-Madoz et al., 2010) . Buffy coats were obtained from the Stanford Blood Center. CD14 + cells were purified from by EasySep™ Human Monocyte Enrichment Kit without CD16 Depletion (Stemcell Technologies). Cells were seeded in 6-well plates (2 × 10 6 cells/well), stimulated with 500 U/ml G-CSF and 1000 U/ml IL-4 (Pepro tech), and incubated at 37°C for 6 days prior to DENV infection (MOI 1).
Generation of MDDCs
Virus production
DENV RNA was transcribed in vitro by mMessage/mMachine (Ambion) kits and electroporated into BHK-21 cells. Supernatant was harvested at day 10 and titered by plaque assays on BHK-21 cells or used to inoculate C6/36 cells to amplify the virus. For mice studies, supernatant was concentrated 100-fold (50,000×g).
In vivo dengue studies
AG B6 mice were generated by crossing C57BL/6.129S2-Ifnar1 tm1Agt /Mmjax (N10) with C57BL/6.129S7-Ifngr1 tm1Agt /J (N11).
Age-matched, male and female mice at 8-10 weeks of age were used. Mouse adapted DENV2 (3 × 10 3 or 3 × 10 4 pfu produced in BHK-21 cells) was inoculated retro-orbitally under general and local anesthesia. Sunitinib (Selleckchem) and erlotinib (LC Laboratories) (both > 95% pure by mass spectrometry) were dissolved in 10% Captisol. 100-200 μl of drugs or vehicle were administered intraperitoneally once daily starting at inoculation for 5 days. Mice were monitored twice daily. Moribund animals were euthanized by CO 2 inhalation. Whole blood was obtained retro-orbitally under general and local anesthesia. Tissues were harvested following euthanasia.
2.6. Virus-inclusive single-cell RNA-Seq
As described (Zanini et al., 2018) , Huh7 cells were infected with DENV at time 0 at MOI 0, 1, or 10, then harvested at different time points, sorted and lysed into single wells. Whole genome mRNA and viral RNA (vRNA) were reverse transcribed and amplified from each cell. Cells were then screened for virus infection by qPCR. Libraries were made and sequenced on an illumina NextSeq 500 with a coverage of ∼400,000 reads per cell.
Gain-of-function assays
Doxycycline-inducible cell lines were established to overexpress AAK1 or GAK via the Flp-In™ recombination system (ThermoFisher) (Torres et al., 2009) . T-REx293 cells with a pFRT/lacZeo site and pcDNA™6/TR were co-transfected with puromycin-resistant vector encoding Flp-In™ recombination target site and pOG44 plasmid containing Flp recombinase followed by puromycin selection. Eight hours post-induction with doxycycline, cells were treated with the drugs, infected with DENV (MOI = 0.01) and incubated for 72 h prior to luciferase and viability assays.
RNA extraction and quantification
RNA extraction and quantification of DENV, AAK1 and GAK RNA were performed as described (Bekerman et al., 2017) .
Viability assays
AlamarBlue
® reagent (Invitrogen) was used according to manufacturer's protocol. Fluorescence was detected at 560 nm on InfiniteM1000 plate reader (Tecan).
Luminex assay
Luminex assay (Stanford Human Immune Monitoring Center). Mouse 38-plex magnetic bead kits (eBioscience/Affymetrix) were added to a 96-well plate and washed in a Biotek ELx405 washer. Serum samples were added in duplicate and incubated at RT for 1 h followed by overnight incubation at 4°C with shaking. Following washing, biotinylated detection antibody was added for 75 min at RT with shaking, followed by washing and addition of streptavidin-PE. After 30-minute incubation at RT and washing, reading buffer was added. Plates were read by Luminex 200. Custom assay control beads (Radix Biosolutions) were added to all wells.
Statistical analysis
Data were analyzed with R or GraphPad Prism softwares. EC 50 s were measured by fitting data to a 3-parameter logistic curve. P values were calculated by one-or two-way ANOVA with various multiple comparisons test or by Mann-Whitney-Wilcoxon test. Survival curve p values were calculated by log-ranked Mantel-Cox test. Correlation coefficients of single-cell transcriptomic data were computed as Spearman's rank correlation ⍴. Error bars are SD of 100 bootstraps over cells.
Study approval
Animal research was conducted under a protocol approved by Stanford Institutional Animal Care and Use Committee and its Institutional Biosafety Committee in compliance with the Animal Welfare Act and other federal regulations relating to experiments involving animalsThe Stanford animal facility is AAALAC-accredited. Moribund mice were humanely euthanized on the basis of IACUC-approved criteria.
Results
3.1. Sunitinib/erlotinib combination provides sustainable protection of mice from severe dengue-associated mortality but not paralysis
The IFN-α/β and IFN-γ receptor-deficient murine model of dengue on 129/Sv (AG-129) and C57BL/6 (AG-B6) genetic backgrounds is widely used for testing candidate antiviral compounds (Bekerman et al., 2017; Schul et al., 2007; Chan et al., 2015) . Depending on the DENV strain and inoculum, these mice either develop a systemic infection that mimics severe dengue or late-onset (day 9-30 postinfection) paralysis associated with DENV replication in the brain (Prestwood et al., 2008; Shresta et al., 2006) . We previously reported that 5-day treatment with sunitinib/erlotinib combination reduced viral load in serum and tissues and early mortality in AG-B6 and AG-129 mice infected with DENV2 (Bekerman et al., 2017) . These experiments were concluded on day 10-12 when the surviving treated animals regained full mobility and displayed weight gain for at least two consecutive days (Bekerman et al., 2017) . Here, we sought to assess whether this protection persists longer. Upon inoculation of AG-B6 mice, we initiated once-daily drug administration at a dose shown to be protective (30 mg/kg of each drug) (Bekerman et al., 2017) . 100% of vehicle-treated mice succumbed to infection on day 5-7 post-infection, whereas a 5-day intraperitoneal sunitinib/erlotinib treatment protected 70% of the mice until day 14, as reported ( Fig. 1A and B) (Bekerman et al., 2017) . Nevertheless, between days 14 and 25 following initiation of treatment, the surviving mice developed paralysis accompanied by weight loss, and were therefore euthanized soon after the onset of paralysis. No paralysis was detected in uninfected mice treated with sunitinib/erlotinib combination, indicating that dengue infection rather than drug treatment mediates this phenotype (data not shown).
To determine whether the observed paralysis resulted from relapsing systemic infection following treatment cessation, we measured viral titers in spleens of dengue-infected AG-B6 mice on various days postinfection by plaque assays. A 5-day once-daily treatment with sunitinib/erlotinib combination reduced the viral titers in the spleen by ∼1 log relative to control mice on day 2 and 4 postinfection and effectively eradicated viral replication by day 6 (Fig. 1C) . Splenic viral titers did not increase on days 8 and 10. In contrast, high DENV titers were measured in the spleens of vehicle control mice until day 6, when all animals succumbed to infection. Next, we measured DENV titers in the brain, spleen, liver and serum of AG-B6 mice that recovered from severe dengue following a 5-day sunitinib/erlotinib treatment course. Samples were collected on day 11 when the first mouse displayed early signs of paralysis. DENV replication was detected in the brain of all these mice, yet it was not associated with systemic infection, as viral titers in spleen, liver and serum samples were undetectable (except for a single sample) (Fig. 1D) .
These results indicate that sunitinib/erlotinib treatment achieves sustained systemic suppression of DENV replication. Nevertheless, treatment does not prevent DENV replication in the brain and late-onset paralysis in this model. We predict that poor BBB permeability of sunitinib and erlotinib hinders their effect in the brain (Oberoi et al., 2013; Verheijen et al., 2017) .
3.2. Sunitinib/erlotinib combination delays paralysis onset in a lowinoculum dengue mouse model
To further study the effect of sunitinib/erlotinib treatment on paralysis, AG-B6 mice were infected at a 10-fold lower DENV inoculum. 100% of sunitinib/erlotinib-treated mice survived beyond day 8 ( Fig. 2A) . In contrast to the high-inoculum model, only ∼50% of the vehicle-treated mice succumbed to death prior to day 8, allowing for controlled monitoring of drug effect on paralysis onset and incidence ( Fig. 2A) . All the surviving vehicle control mice developed paralysis on days 8-14 postinoculation (Fig. 2B ). Sunitinib/erlotinib treatment significantly delayed paralysis onset, and this effect was associated with reduced viral load in the brain relative to vehicle controls, as measured via qRT-PCR assays ( Fig. 2B and C) . These data indicate that sunitinib/ erlotinib treatment has a favorable, yet incomplete effect on paralysis in this low-inoculum model.
Lower dose combination of sunitinib/erlotinib is effective in vivo
Addition of erlotinib decreases sunitinib exposure by 40% (and total active compound exposure, i.e. sunitinib plus its active metabolite, by 20%) relative to sunitinib alone in humans (Blumenschein et al., 2012) . We therefore hypothesized that reducing erlotinib dose may enable sunitinib dose reduction without impairing protection. We conducted dose-finding experiments revealing that 5-day once-daily treatment with sunitinib/erlotinib at 25/20 and 20/15 mg/kg reduced morbidity of DENV-infected mice, albeit the weight of mice treated with the two lower dose regimens plateaued at a lower level on day 7 and did not recover soon after (Fig. 3A) . Nevertheless, treatment with sunitinib/ erlotinib at 25/20 and 20/15 mg/kg performed comparably to the 30/ 30 mg/kg combination in reducing mortality of DENV-infected mice (Fig. 3B) . Sunitinib/erlotinib combination at 15/10 mg/kg exhibited a trend toward delayed mortality, albeit this effect did not meet statistical significance (Fig. 3A and B) . These findings provide evidence for protection with this drug combination at levels at or lower than the corresponding approved cancer dose.
Sunitinib and erlotinib inhibit DENV infection in human dendritic cells
To further determine the feasibility of repurposing sunitinib and erlotinib as anti-DENV drugs, we studied their antiviral effect in primary human MDDCs; an established ex vivo model system for DENV (Rodriguez-Madoz et al., 2010) . We measured a dose-dependent inhibition of DENV infection following a 3-day drug treatment with an EC 50 of 1.962 μM for sunitinib and 4.07 μM for erlotinib by luciferase assays (Fig. 4) , similar to the effect of these drugs in human hepatoma (Huh7) cells (Bekerman et al., 2017) . The concentration range yielding 30 (sunitinib) and 20 fold (erlotinib) reduction in viral infection showed minimal or no cytotoxicity as measured by alamarBlue assays with half-maximal cellular cytotoxicity (CC 50 ) of > 20 μM for sunitinib and > 50 μM for erlotinib (Fig. 4) .
AAK1, but not GAK, gene expression correlates with intracellular DENV abundance
We previously demonstrated a requirement for AAK1 and GAK in DENV infection, thereby validating them as antiviral targets (Bekerman et al., 2017) . Because viruses often modulate host gene expression (Geiss et al., 2000; Walsh and Mohr, 2011) , we sought to determine the effect of DENV infection on AAK1 and GAK expression. DENV infection minimally increased the level of AAK1 and GAK transcripts in bulk Huh7 cell samples relative to uninfected cells, as measured via qRT-PCR at 24 and/or 48 h postinfection (Fig. 5A) . To study this effect while avoiding the averaging process in these bulk samples, we used viscRNASeq (virus-inclusive single-cell RNA-Seq), an approach that we recently developed to sequence and quantify the transcriptome of single cells together with the viral RNA (vRNA) from the same cells (Zanini et al., 2018) . We previously applied viscRNA-Seq to monitor DENV infection in Huh7 cells at various time points postinfection and discovered extreme heterogeneity in virus abundance and a subset of host genes (Zanini et al., 2018) . Here, we directly computed Spearman's rank correlation coefficient between intracellular virus abundance and Fig. 1 . Sunitinib/erlotinib combination protects mice from severe dengue-associated mortality but not from paralysis in a high inoculum model. (A and B) Weight loss (A) and mortality (B) of DENV-infected AG-B6 mice treated once daily for 5 days with sunitinib/erlotinib (SM/E) combination (30 mg/kg each) or vehicle (n = 8 per treatment group). Administration was intraperitoneal and started at inoculation. In A, shown are means ± SD. Dotted line in B represents first onset of paralysis. Mice were euthanized soon after the onset of paralysis. C. DENV titer in spleen of AG-B6 mice measured by plaque assay at various time points following once-daily administration of SM/E combination or vehicle for 5 days (n = 4 per treatment group). Shown are means ± SEM. D. DENV titer in brain, spleen, liver and serum measured by standard plaque assays in AG-B6 mice treated once daily for 5 days with SM/E or vehicle on day 11 postinfection (when the first mouse showed early signs of paralysis, n = 6 per treatment group). Representative experiments out of two conducted are shown. Dotted lines represent limit of detection (100 PFU (C) and 10 PFU (D)). *P < 0.05, ***P < 0.001 relative to vehicle control by log-rank test (B) and two-way ANOVA with Bonferroni multiple comparisons test (C). ND, not detected; NA, not applicable. Administration was intraperitoneal and started at inoculation. Data pooled from two independent experiments is shown. Dotted line represents first onset of paralysis. Mice were euthanized soon after the onset of paralysis. C. DENV load in the brain of AG-B6 mice on day 8-12 postinoculation with a low DENV titer and once daily 5-day treatment with SM/E combination (n = 13) or vehicle (n = 5). *P < 0.05 relative to vehicle control by log-rank test (A, B) and nonparametric Mann-Whitney-Wilcoxon test (C). GE, genome equivalent; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
transcript level for AAK1 and GAK. The expression of AAK1 significantly increased upon DENV infection at MOI of 1 and 10 in correlation with the intracellular virus abundance within single cells (⍴ = 0.26 and 0.22, respectively) (Fig. 5B) . To disentangle the effect of time since infection from the vRNA level within each cell, we computed the same correlation coefficient within single time points. The correlation of AAK1 with virus abundance slightly declined in the first 10 h but then increased during the course of infection, with a ⍴ value of > 0.4 at 50 h postinfection, indicating a strong correlation (Fig. 5C ). In contrast, GAK level did not correlate with vRNA level in the same cells (⍴ = -0.03˗-0.07) ( Fig. 5B and C) .
AAK1 and GAK are molecular targets underlying the antiviral effect of sunitinib and erlotinib
Next, we conducted gain-of-function assays, to confirm that inhibition of AAK1 and GAK is a mechanism underlying the anti-DENV effect of these drugs. Following doxycycline-mediated induction of AAK1 or GAK expression, T-REx 293 cells were infected with a luciferase reporter DENV and treated with sunitinib or erlotinib for 72 h prior to luciferase and viability assays. Doxycycline-induced AAK1 and GAK expression either partially or completely reversed the antiviral effect of sunitinib and erlotinib, respectively, relative to uninduced cells (Fig. 6) . These results validate AAK1 and GAK as key mediators of the anti-DENV effect of sunitinib and erlotinib.
Protection of dengue infected mice by sunitinib/erlotinib treatment is associated with altered cytokine responses
To better understand the MOA underlying the in vivo anti-DENV activity of these drugs, we studied the effect of daily sunitinib/erlotinib treatment on the levels of 38 cytokines in the serum of dengue-infected AG-B6 mice and uninfected controls at 48 and 72 h postinoculation via a Luminex assay. Sunitinib/erlotinib treatment did not alter cytokine levels in uninfected mice (Fig. S1 ). As reported in this model (Costa et al., 2013; Soo et al., 2017) , dengue infection increased the levels of multiple cytokines, including tumor necrosis factor (TNF)-á, interleukin (IL)-6, IL-10, IL-18, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1á, MIP-1â, and interferon (IFN)-γ (Fig. S1 ). Sunitinib/erlotinib treatment of dengue-infected mice increased the levels of the innate immune response cytokines MIP1-â, MCP-1, and IL-22 as well as IL-31, a cytokine associated with cellmediated immunity against microbial pathogens, at 48 and/or 72 h following treatment (Fig. 7) . Additionally, sunitinib/erlotinib treatment significantly reduced the level of the proinflammatory cytokine IL-18 ( Fig. 7 and Fig. S1 ). These findings suggest that in addition to inhibiting intracellular viral trafficking (Bekerman et al., 2017) , sunitinib/erlotinib treatment alters host cytokine responses.
Discussion
We previously reported that sunitinib/erlotinib combination protects mice from DENV and EBOV infections, in part via inhibition of AAK1-and GAK-regulated intracellular viral trafficking (Bekerman et al., 2017) . Nevertheless, better understanding of the therapeutic potential and MOA of this approach is warranted prior to advancing it into clinic. Here, we address these gaps and further demonstrate feasibility and biological rationale in repurposing sunitinib/erlotinib as anti-DENV drugs.
Our data indicate that the suppressive effect of 5-day treatment with sunitinib/erlotinib combination on systemic DENV replication in mice is sustainable. Treatment thus prevents progression to severe dengue rather than delays its onset. Notably, this treatment delays, but does not prevent the development of late-onset paralysis observed in this animal model. Poor BBB permeability may explain lack of viral control in the brain of infected animals (Oberoi et al., 2013; Verheijen et al., 2017) . While neurological manifestations can complicate clinical dengue infection, they are primarily attributed to toxic and metabolic processes or post-infectious inflammation, and rarely to DENV replication in the brain (Solomon et al., 2000) . The relevance of paralysis, commonly observed in dengue mouse models, to human infection is thus questionable (Prestwood et al., 2008; Shresta et al., 2006) . Additionally, the Fig. 3 . Lower dose combinations of sunitinib/erlotinib are effective in vivo. Weight loss (A) and mortality (B) of DENV-infected AG-B6 mice treated once daily for 5 days with sunitinib/erlotinib (SM/E) combination at the indicated doses (mg/kg) or vehicle (n = 8 per treatment group, per experiment). Administration was by gavage and started at inoculation. Data pooled from three independent experiments is shown. In A, shown are means ± SD. P by log-rank test are relative to vehicle control or between the various tested groups as indicated (B) . N.S, non-significant. Fig. 4 . Ex vivo antiviral activity of sunitinib and erlotinib in human primary dendritic cells. Cell viability (blue) and dose response of DENV infection (black) to sunitinib (left) and erlotinib (right) measured by alamarBlue assays and luciferase assays, respectively, 72 h after infection of primary human MDDCs. Data are plotted relative to vehicle control. Shown is a representative experiment with cells from a single donor, out of 3 independent experiments conducted with cells derived from 3 donors, each with 5 biological replicates; shown are means ± SD. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) immunosuppressed status of AG-B6 mice likely played a role in limiting viral clearance. These data therefore do not propose that drug candidates for the treatment of dengue should be BBB-permeable, but rather highlight the limitations of this model. Additionally, while treatment was administered intraperitoneally (Figs. 1 and 2) , we have previously reported that this combination treatment proved comparably efficacious with either intraperitoneal or oral administration (Bekerman et al., 2017) .
Sunitinib and erlotinib are approved individually for the treatment of various cancers at a maximum once-daily oral dose of 37.5 mg and 150 mg, respectively. The 30 mg/kg intraperitoneal dose of sunitinib and erlotinib in mice was previously shown to yield serum drug concentrations comparable to those achieved in humans at the approved dose and is below the maximum tolerated dose in mice (Bekerman et al., 2017; Higgins et al., 2004; Mendel et al., 2003; Nair and Jacob, 2016) . It was efficacious and similarly well tolerated in the dengue model (Bekerman et al., 2017) . Nevertheless, per the FDA's guidelines for drug dose conversion based on the body surface area (Nair and Jacob, 2016) , 30 mg/kg sunitinib mouse dose is 3-fold higher than the approved human dose, while 30 mg/kg erlotinib dose is equivalent. Furthermore, because repurposing of approved anticancer drugs for an antiviral indication may require meeting more stringent safety criteria, demonstrating antiviral efficacy at the lowest possible dose is desirable. Our finding that oral administration of sunitinib/ erlotinib combinations at 25/20 and 20/15 mg/kg are protective similarly to the previously reported 30/30 dose, suggests that finding a safe therapeutic dose lower than that approved in oncology may be feasible. It is possible that an increase in sunitinib metabolite, whose activity in other models is comparable to that of sunitinib, partially compensates for the concurrent decrease of sunitinib exposure upon erlotinib treatment (Bello et al., 2006; Blumenschein et al., 2012; Noé et al., 2016) . Sunitinib/erlotinib combination has already been shown to be tolerated in ∼1000 cancer patients, albeit with increased gastrointestinal adverse events (Blumenschein et al., 2012; Scagliotti et al., 2012) . However, a shift from the long-term cancer treatment to acute dengue infection treatment should improve tolerance and minimize adverse effects.
Dendritic cells represent the primary target of DENV in humans. Moreover, primary cells better model human physiology and disease than immortalized cell lines (Schmid et al., 2014) . Our finding that sunitinib and erlotinib treatment exhibits antiviral efficacy in MDDCs with minimal toxicity to host cells thus further supports the biological relevance of this approach.
Our single-cell transcriptomic data reveals a strong correlation between AAK1 expression and intracellular virus abundance. Since the expression distribution in infected cells shifts beyond the tails of the expression distribution in uninfected cells, it is likely that the expression change is triggered by infection rather than representing a preexisting level setting permissive conditions for infection. We have recently reported that most human genes do not correlate with the intracellular vRNA (Zanini et al., 2018) . AAK1 is thus among the small subset of genes, many of which are proviral factors (Zanini et al., 2018 ), that correlate with virus level in the same cells. This finding further validates AAK1 as an attractive antiviral target and proposes that like in cancer (Paul and Mukhopadhyay, 2004) , targeting overexpressed proviral kinases in virally-infected cells may facilitate an effective means to suppress viral infection. Moreover, these data underscore the utility of the single-cell transcriptomic approach to characterize host response to viral infection at high resolution by combining temporal information, cell-to-cell variability, and high-quality expression data. While GAK gene level slightly increased in bulk samples, it did not correlate with vRNA in single cells. This may reflect our finding that mean values measured via bulk assays are inflated and tend to over-represent highly infected cells (Zanini et al., 2018) . Alternatively, our single-cell coverage (∼400,000 reads/cell) may be too low to detect smaller changes in transcript level.
Our gain-of-function assays support inhibition of AAK1 and GAK activity as an important mode of antiviral action of sunitinib and erlotinib. Nevertheless, we cannot exclude the possibility that other targets of sunitinib, such as AXL, KIT and RET, which may be essential for DENV infection (Bekerman et al., 2017) , are involved in mediating this antiviral effect. Beyond suppression of AAK1-and GAK-mediated intracellular viral trafficking, our data suggest that alterations in cytokine responses may also contribute to the protective effect of sunitinib/erlotinib in dengue-infected mice. Some cytokines whose level is increased by sunitinib/erlotinib treatment are implicated in protecting from severe dengue or are associated with uncomplicated dengue. Elevated MIP-1â level is associated with NK cell activation and protection from development of severe dengue in patients (Azeredo et al., 2006; Bozza et al., 2008) . MCP-1 levels are higher in mice inoculated with DENV isolates obtained from patients with dengue fever relative to severe dengue (Tuiskunen et al., 2011) . IL-22 is protective in a dengue mouse model (Guabiraba et al., 2013) and its polymorphism is associated with hepatitis C virus clearance (Hennig et al., 2007) . The increased level of the two chemokines MIP-1â and MCP-1 (Sokol and Luster, 2015) and of IL-22 (Wolk et al., 2004) suggests that sunitinib/erlotinib treatment may augment innate immune responses. The increase in IL-31, a cytokine associated with cell-mediated immunity (Hermanns, 2015) , suggests that treatment may also affect the adaptive immune system. Sunitinib/erlotinib treatment also significantly reduced the level of the proinflammatory cytokine IL-18, whose elevated level in severe dengue is thought to contribute to the pathogenesis of dengue hemorrhagic fever (Mustafa et al., 2001; Soo et al., 2017) . This is an attractive feature of sunitinib/erlotinib treatment, as it suggests they may benefit patients not only by inhibiting viral infection, but also by altering cytokine responses in a way that shifts the balance from pathogenesis to viral clearance. It remains to be determined whether inhibition of AAK1 and GAK or other kinases mediates this altered cytokine responses. Alternatively, it is possible that these drugs' effect on cytokine production results from reduced viral burden via their effect on viral replication. Since AG-B6 mice are immunodeficient, the relevance of these cytokine alterations to human dengue infection remains to be determined.
In summary, our study provides further evidence for the utility of two clinically approved compounds as potential therapies against DENV infection and novel insight into their MOA. This repurposed approach may provide additive and possibly synergistic effects in combination with other strategies being developed to combat dengue and other emerging viral infections. DENV infection normalized to cellular viability in these cells via luciferase and alamarBlue assays, respectively, 72 h following infection with a luciferase reporter DENV and treatment with sunitinib (B) or erlotinib (C). Shown is a representative experiment out of two conducted, each with 5 replicates. *P < 0.05, **P < 0.01 relative to induced or uninduced cells treated with DMSO by one-way ANOVA with Fisher's least significant difference test. Means ± SD are shown. Fig. 7 . Sunitinib/erlotinib combination alters inflammatory cytokines levels in the serum of dengue infected mice. Cytokines levels measured by Luminex assay in AG-B6 mice 48 or 72 h postinfection with DENV or in uninfected mice following once-daily administration of vehicle or sunitinib/erlotinib (SM/E) combination. Shown are box plots of the concentrations of the indicated cytokines. The box horizontal lines indicate the first, second (median) and third quartiles. Outliers above the upper whisker (Q3+1.5xIQR) or below the lower whisker (Q1-1.5xIQR) are labeled with black lines. n = 8 per infected treatment group and 2-3 per uninfected group treated with vehicle or sunitinib/erlotinib combination, respectively. *P < 0.05 and ***P < 0.001 relative to untreated infected mice by 2-way ANOVA with Tukey's multiple comparisons test. IQR, interquartile range; NS, Non-Significant.
